ADMA Financial Statements From 2010 to 2025

ADMA Stock  USD 19.11  0.17  0.88%   
ADMA Biologics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing ADMA Biologics' valuation are provided below:
Gross Profit
267.3 M
Profit Margin
0.4287
Market Capitalization
4.6 B
Enterprise Value Revenue
9.4366
Revenue
488.6 M
We have found one hundred twenty available fundamental signals for ADMA Biologics, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of ADMA Biologics prevailing market performance against the performance between 2010 and 2025 to make sure the company can sustain itself in the future. The current year's Market Cap is expected to grow to about 4.2 B. The current year's Enterprise Value is expected to grow to about 4.2 B

ADMA Biologics Total Revenue

447.78 Million

Check ADMA Biologics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ADMA Biologics' main balance sheet or income statement drivers, such as Interest Expense of 14.6 M, Other Operating Expenses of 301.8 M or Operating Income of 145.9 M, as well as many indicators such as Price To Sales Ratio of 11.31, Dividend Yield of 0.0694 or PTB Ratio of 12.03. ADMA financial statements analysis is a perfect complement when working with ADMA Biologics Valuation or Volatility modules.
  
Build AI portfolio with ADMA Stock
Check out the analysis of ADMA Biologics Correlation against competitors.
For information on how to trade ADMA Stock refer to our How to Trade ADMA Stock guide.

ADMA Biologics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets513.1 M488.7 M164 M
Slightly volatile
Short and Long Term Debt Total50.7 M82.1 M55.1 M
Slightly volatile
Total Current Liabilities58.3 M55.5 M20.1 M
Slightly volatile
Cash108.3 M103.1 M40 M
Slightly volatile
Common Stock Shares Outstanding360.7 M243.3 M167 M
Very volatile
Liabilities And Stockholders Equity513.1 M488.7 M164.3 M
Slightly volatile
Total Liabilities146.6 M139.7 M79.5 M
Slightly volatile
Total Current Assets348 M331.4 M118.1 M
Slightly volatile
Other Current Liabilities32 M30.5 M11 M
Slightly volatile
Cash And Short Term Investments108.3 M103.1 M41.2 M
Slightly volatile
Common Stock Total Equity19 K20 K24 K
Slightly volatile
Non Current Liabilities Total54.7 M84.1 M57.7 M
Slightly volatile
Other Stockholder Equity690.5 M657.6 M294.4 M
Slightly volatile
Common Stock29.1 K24 K24.9 K
Pretty Stable
Property Plant And Equipment Net66.5 M63.3 M29.4 M
Slightly volatile
Accounts Payable21.2 M20.2 M7.9 M
Slightly volatile
Non Current Assets Total165.1 M157.3 M46.1 M
Slightly volatile
Inventory178.7 M170.2 M62.1 M
Slightly volatile
Other Current Assets8.4 MM2.8 M
Slightly volatile
Property Plant And Equipment Gross101.7 M96.9 M34.2 M
Slightly volatile
Other LiabilitiesM4.2 M140.2 M
Pretty Stable
Long Term Debt60 M72.3 M48.5 M
Slightly volatile
Long Term Debt Total84 M80 M39.2 M
Slightly volatile
Capital Surpluse760.7 M724.5 M307.8 M
Slightly volatile
Capital Lease Obligations10.3 M9.8 M3.6 M
Slightly volatile
Deferred Long Term Liabilities2.3 M2.6 M1.9 M
Slightly volatile
Non Current Liabilities Other1.6 M1.7 M5.2 M
Very volatile
Short Term Debt1.2 M1.2 M945.6 K
Pretty Stable
Property Plant Equipment63.7 M67 M2.9 B
Pretty Stable
Current Deferred Revenue148.8 K143 K124.9 K
Slightly volatile
Deferred Long Term Asset Charges231.7 K312.4 K241.2 K
Slightly volatile
Short and Long Term Debt48.6 M46.2 M23.9 M
Slightly volatile
Net Invested Capital227.7 M421.4 M154.2 M
Slightly volatile
Net Working Capital163.2 M275.9 M107.9 M
Slightly volatile
Capital Stock17.3 K24 K10.3 K
Slightly volatile

ADMA Biologics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses301.8 M287.5 M100.3 M
Slightly volatile
Total Operating Expenses84.6 M80.6 M39 M
Slightly volatile
Selling General Administrative77.8 M74.1 M29 M
Slightly volatile
Depreciation And Amortization8.4 MM3.2 M
Slightly volatile
Total Revenue447.8 M426.5 M94.3 M
Slightly volatile
Research Development1.7 M1.8 M4.8 M
Slightly volatile
Cost Of Revenue217.2 M206.9 M61.4 M
Slightly volatile
Interest Income2.2 M2.1 M1.1 M
Pretty Stable
Non Recurring676.3 K760.9 K829.5 K
Slightly volatile
Reconciled Depreciation5.8 MM4.2 M
Slightly volatile

ADMA Biologics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow28.5 M51.4 M29.9 M
Slightly volatile
End Period Cash Flow108.3 M103.1 M40.6 M
Slightly volatile
Depreciation8.4 MM3.3 M
Slightly volatile
Stock Based Compensation14.3 M13.6 M3.7 M
Slightly volatile
Change To Netincome18.5 M17.6 M5.5 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio11.319.373614.0929
Slightly volatile
Dividend Yield0.06940.07810.0851
Slightly volatile
Days Sales Outstanding41.0242.793944.0912
Slightly volatile
Average Payables6.5 M11.5 M6.9 M
Slightly volatile
Stock Based Compensation To Revenue0.03030.03190.1886
Slightly volatile
Capex To Depreciation1.971.06591.6578
Very volatile
EV To Sales10.679.324212.6203
Slightly volatile
Inventory Turnover1.361.21541.1563
Very volatile
Days Of Inventory On Hand294300403
Slightly volatile
Payables Turnover10.7410.2334.8994
Slightly volatile
Sales General And Administrative To Revenue1.41.521.5044
Slightly volatile
Average Inventory158.8 M151.3 M61 M
Slightly volatile
Research And Ddevelopement To Revenue0.0040.00431.0289
Slightly volatile
Capex To Revenue0.01910.02010.1109
Pretty Stable
Cash Per Share0.420.44251.6077
Slightly volatile
Days Payables Outstanding33.8935.6689200
Slightly volatile
Intangibles To Total Assets0.00780.00820.0529
Slightly volatile
Current Ratio3.75.96685.7337
Very volatile
Receivables Turnover11.248.529312.905
Slightly volatile
Graham Number4.284.815.2453
Slightly volatile
Capex Per Share0.03490.03680.0624
Very volatile
Average Receivables20.8 M19.8 M8.1 M
Slightly volatile
Revenue Per Share1.921.82960.7482
Slightly volatile
Interest Debt Per Share0.390.41211.3176
Slightly volatile
Debt To Assets0.160.1680.4394
Pretty Stable
Operating Cycle332343446
Pretty Stable
Days Of Payables Outstanding33.8935.6689200
Slightly volatile
Long Term Debt To Capitalization0.160.17170.5483
Pretty Stable
Total Debt To Capitalization0.180.19050.545
Pretty Stable
Quick Ratio3.052.90193.8516
Slightly volatile
Net Income Per E B T0.941.421.1357
Slightly volatile
Cash Ratio1.961.85713.1394
Slightly volatile
Days Of Inventory Outstanding294300403
Slightly volatile
Days Of Sales Outstanding41.0242.793944.0912
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.110.92771.0212
Pretty Stable
Fixed Asset Turnover7.076.73272.7111
Slightly volatile
Debt Ratio0.160.1680.4394
Pretty Stable
Price Sales Ratio11.319.373614.0929
Slightly volatile
Asset Turnover0.920.87270.3394
Slightly volatile

ADMA Biologics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap4.2 BB695.3 M
Slightly volatile
Enterprise Value4.2 BB710.2 M
Slightly volatile

ADMA Fundamental Market Drivers

Forward Price Earnings28.9855
Cash And Short Term Investments103.1 M

ADMA Upcoming Events

28th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
28th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About ADMA Biologics Financial Statements

ADMA Biologics stakeholders use historical fundamental indicators, such as ADMA Biologics' revenue or net income, to determine how well the company is positioned to perform in the future. Although ADMA Biologics investors may analyze each financial statement separately, they are all interrelated. For example, changes in ADMA Biologics' assets and liabilities are reflected in the revenues and expenses on ADMA Biologics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in ADMA Biologics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue143 K148.8 K
Total Revenue426.5 M447.8 M
Cost Of Revenue206.9 M217.2 M
Stock Based Compensation To Revenue 0.03  0.03 
Sales General And Administrative To Revenue 1.52  1.40 
Capex To Revenue 0.02  0.02 
Revenue Per Share 1.83  1.92 
Ebit Per Revenue 0.33  0.34 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether ADMA Biologics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ADMA Biologics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Adma Biologics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Adma Biologics Stock:
Check out the analysis of ADMA Biologics Correlation against competitors.
For information on how to trade ADMA Stock refer to our How to Trade ADMA Stock guide.
You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ADMA Biologics. If investors know ADMA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ADMA Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
0.85
Revenue Per Share
2.053
Quarterly Revenue Growth
0.12
Return On Assets
0.2176
Return On Equity
0.6317
The market value of ADMA Biologics is measured differently than its book value, which is the value of ADMA that is recorded on the company's balance sheet. Investors also form their own opinion of ADMA Biologics' value that differs from its market value or its book value, called intrinsic value, which is ADMA Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ADMA Biologics' market value can be influenced by many factors that don't directly affect ADMA Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ADMA Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ADMA Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ADMA Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.